Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
Merck, Moderna melanoma vaccine succeeds
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial IOL —
- Merck, Moderna Melanoma Vaccine Study Succeeds Bloomberg —
- Merck, Moderna claim encouraging melanoma vaccine trial results South China Morning Post —
- Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning The New York Times —
- Merck, Moderna Stocks Soar After Melanoma Trial Success 📹 Bloomberg — · 2min